SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

Escalating US-Israeli strikes on Iran are fueling intense community discussion around USO, with many anticipating significant oil price spikes and a global supply shock as shipping through the vital Strait of Hormuz faces increasing disruptions.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating Middle East tensions, including strikes on Iran and concerns over disruptions in the vital Strait of Hormuz, are driving a surge in crude oil prices and fueling community discussion around Indonesia Energy Corp Ltd's potential for a significant short squeeze given its low float.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is surging as escalating Middle East tensions, particularly involving Iran and threats to the Strait of Hormuz, are driving strong community conversation around a significant potential for global oil supply disruption. Traders are widely discussing a rotation into energy, anticipating XLE will benefit from a material rise in crude prices.

Codatta

Codatta (XNY) is trending as the crypto community highlights its impressive price resilience and ability to show strength even during broader market pullbacks, leading to active discussions around its consistent breaking of resistance and establishing new support levels for potential further upside.

CECO Environmental Corp. engages in the provision of engineering technology and solutions. It offers services in the field of environment, energy, fluid handling, and filtration. The firm operates through the following segments: Energy Solutions, Industrial Solutions and Fluid Handling Solutions. The Energy Solutions segment improves air quality and solves fluid handling needs with market engineered, and customized solutions for the power generation, oil and gas, and petrochemical industries. The Industrial Solutions segment serves the industrial pollution control market. The Fluid Handling Solutions segment provides pump and filtration solutions that maintain safe and clean operations in some of the most harsh and toxic environments. The company was founded by Phillip DeZwirek in 1966 and is headquartered in Austin, TX.

Ceco Environmental Corp.

CECO Environmental is trending due to its recent $2.2 billion Thermon acquisition, aimed at creating a global leader in environmental and thermal solutions, though the news prompted a surprising sell-off despite raised 2026 guidance. The community is actively debating whether the dip is an unjustified reaction and a buying opportunity, contrasting it with the company's strong backlog and optimistic analyst ratings.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is trending as a community-driven memecoin, hailed as the "third frog" and the official representation of Pepe's post-4chan experience, leveraging a diehard community that champions its unique narrative. The community is actively discussing its impressive resilience and immense upside potential as a micro-cap project within the prominent frog-themed crypto meta.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid escalating Middle East conflict following US/Israeli strikes and Iranian retaliation, leading to intense market debate over a potential downturn driven by rising oil prices or a quick rebound on hopes for a swift resolution.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as escalating U.S.-Iran tensions and military posturing drive concerns over potential oil supply disruptions, particularly in the critical Strait of Hormuz, leading the community to anticipate substantial gains for the energy giant.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as escalating Middle East tensions fuel speculation of oil price spikes, with the community actively debating if these geopolitical risks and the company's strategic positioning in Venezuela are fully priced into the broadly outperforming energy sector.

Confluent, Inc. engages in creating a data infrastructure platform focused on data in motion. The firm provides application architecture engagement, multi data center, security and upgrade engagement, and Amazon web services cloud deployment services. Its products include Confluent Cloud, Confluent Platform, WarpStream BYOC, Connectors, Flink, Stream Governance, and Confluent Hub. The company was founded by Edward Jay Kreps, Neha Narkhede, and Jun Rao on September 1, 2014, and is headquartered in Mountain View, CA.

Confluent Inc - Ordinary Shares Class A

Confluent Inc

Confluent is actively trending following the confirmed $11 billion all-cash acquisition by IBM for $31 per share, sparking community discussion around why the stock isn't precisely at the buyout price and how Confluent's real-time data streaming platform strengthens IBM's AI and hybrid cloud ambitions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galecto (NASDAQ:GLTO) CEO Hans Schambye Sells 700 Shares

Galecto, Inc. (NASDAQ:GLTO - Get Free Report) CEO Hans Schambye sold 700 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $21.38...

Is the Market Bullish or Bearish on Galecto Inc?

Galecto (NASDAQ:GLTO) Shares Down 13.3% - Time to Sell?

Galecto (NASDAQ:GLTO) Stock Price Down 13.3% - Here's Why...

Small Cap Stocks To Watch Today - November 11th

Spring Valley Acquisition, enGene, Canadian Solar, Galecto, RealReal, Daily Journal Corp. (S.C.), and Navitas Semiconductor are the seven Small Cap stocks to watch today, according to MarketBeat's...

Small Cap Stocks To Research - November 10th

Spring Valley Acquisition, Galecto, Movano, Papa John's International, Strive, Inflection Point Acquisition Corp. II, and Direxion Daily PLTR Bull 2X Shares are the seven Small Cap stocks to watch...

<ul class="summary-bullets"><li>Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.</li><li>The deal adds Damora’s portfolio of mutant calreticulin–targeting antibody therapies for rare blood cancers, with early human trial data expected in 2027.</li><li>The acquisition positions Galecto to focus on next-generation treatments for myeloproliferative neoplasms, expanding its cancer pipeline alongside its ongoing AML drug program.</li></ul>Shares of Galecto surged nearly&nbsp;25% in premarket trading on Tuesday after the biotech firm announced the acquisition of Damora Therapeutics, a private company developing next-generation antibody drugs for rare blood cancers.<h2 class="st-heading-2">Galecto Bets Big On Blood Cancer Therapies</h2>The acquisition gives Galecto control of Damora’s pipeline of mutant calreticulin (mutCALR)-targeting therapies, including DMR-001, a monoclonal antibody that aims to treat two difficult-to-manage bone marrow cancers, which are essential thrombocythemia and myelofibrosis. The company said the drug could be “best in class,” with the potential to work across a broad range of disease-driving mutations.As part of the deal, Galecto raised $285 million in a private round that drew some of the biggest names in biotech investing, including Viking Global Investors, RA Capital Management, Wellington Management, Blackstone, BB Biotech, and Andreessen Horowitz’s a16z Bio + Health. The funding gives the company enough cash to operate well into 2029, with early human trial data for DMR-001 expected in 2027.<h2 class="st-heading-2">A New Chapter For Galecto</h2>Galecto CEO Hans Schambye called the deal a “pivotal milestone” that positions the company to accelerate next-generation treatments for blood cancers driven by mutCALR, which account for roughly 25% of essential thrombocythemia and 35% of myelofibrosis cases in the U.S.Incoming board member Peter Harwin, managing partner at Fairmount, said the combined financial and clinical resources will enable Galecto to advance DMR-001 from preclinical to human testing by mid-2026, with the goal of offering a safer, more convenient treatment option for patients.<h2 class="st-heading-2">Growing Its Cancer Pipeline</h2>Beyond Damora’s assets, Galecto said it’s also advancing its own drug, GB3226, for acute myeloid leukemia (AML). The compound will be featured at the American Society of Hematology’s annual meeting in December, with an FDA filing expected in early 2026 to begin human testing.<h2 class="st-heading-2">Stocktwits Users Eye Multi-Day Rally</h2>On Stocktwits, retail sentiment for Galecto was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:962/134;" src="https://news.stocktwits-cdn.com/glto_ss_jpg_87be36e195.webp" alt="glto ss.jpg" width="962" height="134"><figcaption>GLTO sentiment and message volume as of November 11 | Source: Stocktwits</figcaption></figure>One user speculated that Galecto’s stock could turn into a “multi-day runner,” hinting at continued momentum after its sharp surge.<stembedurl>https://stocktwits.com/Bcscoatings/message/635686140</stembedurl>Another user was far more bullish, predicting the stock could hit $50 next and even climb toward $150.<stembedurl>https://stocktwits.com/BearBullRunner/message/635681400</stembedurl><a href="https://stocktwits.com/symbol/GLTO">Galecto’s stock</a> has surged by more than 270% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Galecto Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally

Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.

Equity

Shares of biotechnology company Galecto, Inc. (GLTO) soared 632% in the pre-market session on Tuesday. The stock is on track to hit over two-year highs.Galecto is focused on developing treatments for oncological and liver diseases. Its pipeline consists of drug candidates that target cancer and fibrosis signaling pathways, including GB1211 for the treatment of liver cirrhosis, GB1211 in combination with a checkpoint inhibitor for various oncology indications, and GB3226 for multiple genetic subsets of Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GLTO">GLTO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1362/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_8_17_12_AM_png_631ad32651.webp" alt="GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1362" height="124"><figcaption>GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that this is a pump-and-dump move.<stembedurl>https://stocktwits.com/moneytra1n/message/631281671</stembedurl>Another believes that the rally could be short-lived.<stembedurl>https://stocktwits.com/come_litaliano/message/631283183</stembedurl>In August, Galecto CEO Hans Schambye announced that the company is looking forward to submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2026 for its lead program, GB3226. Preclinical data support the therapeutic potential of the candidate as a monotherapy and in combination to address the menin-resistant population within AML, the company said.Galecto ended the second quarter with approximately $10.2 million in cash and cash equivalents. Last month, it said that it expects this amount to be sufficient to fund operating expenses and capital requirements into 2026, including the submission of the investigational new drug application for GB3226.The company also noted that it would require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.GLTO stock is down by 20% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jlr-begins-phased-restart-of-operations-more-than-a-month-after-cyber-incident/ch6P7elR3WM">JLR Begins Phased Restart Of Operations More Than A Month After Cyber Incident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious

Galecto is focused on developing treatments for oncological and liver diseases.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

GLTO
Galecto Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLTO News

GLTOGalecto Inc